NCT03289741 2025-05-09
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
Memorial Sloan Kettering Cancer Center
Phase 4 Completed
Memorial Sloan Kettering Cancer Center
University College Hospital, Ibadan
Novartis
Novartis
Novartis
Novartis